News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

American Society of Clinical Oncology Presentation Shows Sequenta, Inc.'s Lymphosight™ Technology is Highly Predictive of Survival in Multiple Myeloma Patients


6/3/2013 12:14:39 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO – Researchers from Hospital Universitario 12 de Octubre presented data today at the American Society of Clinical Oncology Annual Meeting (ASCO) that demonstrated the power of Sequenta’s LymphoSIGHT™ platform for the detection of minimal residual disease (MRD) in multiple myeloma patients. The oral presentation described how researchers compared Sequenta’s proprietary sequencing method with other technologies for assessing MRD levels following standard therapy. Sequenta’s LymphoSIGHT platform was demonstrated to be highly concordant with flow cytometry but showed a significant prognostic improvement over protein assays delivered as standard of care. “Molecular assessment of residual disease following initial therapy is redefining complete response in multiple myeloma patients,” said Joaquin Martinez, the lead researcher on the study. “As the therapeutic approaches to myeloma are revolutionized by new drugs, sensitive, scalable assays for MRD assessment such as this LymphoSIGHT assay will be critical to determining optimal individualized therapy.”

The study encompassed more than 100 bone marrow samples from 56 patients enrolled in Spanish Myeloma Trials (GEM00 and GEM05) who were followed post-treatment. MRD positivity strongly predicted time to progression. Importantly, amongst patients in conventional complete response, MRD positivity by the LymphoSIGHT method was highly predictive of progression-free and overall survival.

“This study serves to extend the clinical validation of the LymphoSIGHT platform into an important new disease area,” said Tom Willis, CEO of Sequenta. “In addition to providing clinical trial services to support trials such as this, we are currently offering the ClonoSIGHT™ test, the first clinically actionable sequencing based MRD test, through our CLIA-certified laboratory.”

This study is one of three presentations of the LymphoSIGHT platform at ASCO. Additional presentations include a separate study showing the prognostic performance of the LymphoSIGHT platform in the multiple myeloma transplant setting, as well as the ability of this platform to elucidate immune responses to CTLA-4 inhibitors.

About Sequenta, Inc.

Sequenta is a venture backed startup dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. For more information, go to www.sequenta.com.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES